FDA written feedback supports a potential pivotal expansion of REO 033 using response rate and duration as an accelerated-approval strategy, but Oncolytics must first generate supportive randomized Part A data.
Explore how Oncolytics Biotech, Inc.’s pelareorep data could reshape MSS colorectal cancer care. Discover durability insights and what comes next.
Can Oncolytics Biotech move pelareorep closer to approval in anal cancer? Read what the FDA meeting could change for clinicians and investors.
Find out why Oncolytics Biotech’s latest GOBLET cohort 4 data could reshape immunotherapy strategies for third-line anal cancer.